Learn · regulatory literacy

What does an FDA advisory committee vote actually change?

Legally, nothing - on the day of the vote. An FDA advisory committee recommendation does not bind the agency, amend any list, or authorize anything. On July 23-24, 2026 the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A compounding list; as of today, not one of them is legal to compound. The vote matters as a signal of direction, not as a change in the law.

Published Aug 21, 2026 (ET) · every claim sourced below

The July 2026 votes, as the case study

The committee reviewed seven peptides across two days and voted to recommend six - including BPC-157 (8-6, one abstention), TB-500 and Semax - overriding the FDA's own review staff, whose briefing documents had proposed against listing all seven. Headlines read it as the FDA clearing them. It was not that: every vote and tally is here, and none moved a legal status.

What has to happen next is the part headlines skip: the FDA must decide to accept a recommendation, publish a proposed rule in the Federal Register, take public comment for roughly 60 to 90 days, and issue a final rule. That is generally a 12-to-24-month process, the agency has not started it, and it is not obliged to start it at all.

Why the committee exists if its votes do not bind

Advisory committees give the FDA outside scientific opinion on contested questions - in this case, whether each substance's characterization, safety evidence, and clinical need justify pharmacy compounding. A favorable vote is genuine forward motion: it is the strongest public signal a nominated substance can get short of rulemaking itself. That is exactly why Peptlas marks recommended-but-unlisted compounds as in limbo rather than either legal or halted - the honest description of a status that moved in signal but not in law.

A second meeting is coming: the FDA has signalled a further PCAC session on five more substances (LL-37, GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF) before the end of February 2027, without publishing a date - what is known about that meeting is tracked here. Each entry it touches will change status the day something official happens - the alert list exists for exactly that moment.

Current statuses mentioned here

Asked and answered

Did the FDA approve BPC-157 and the other peptides in July 2026?
No. An advisory committee recommended six of seven reviewed peptides for the 503A compounding list. The recommendation does not bind the FDA, and no legal status changed. None of the seven is legal to compound today.
Can the FDA ignore an advisory committee vote?
Yes. The votes are advisory by design. The FDA often follows its committees, but it is free not to, and there is no deadline forcing it to respond.
When would a recommended peptide actually become legal to compound?
Only after the FDA completes notice-and-comment rulemaking - a proposed rule, a comment period, and a final rule, generally estimated at 12 to 24 months. The agency has not begun that process for any of the July 2026 peptides.

Sources

Keep going

What is the FDA's 503A bulk substances list?Was BPC-157 banned - or approved? Neither.All learn articlesThe full atlas